AbbVie seeks FDA approval for blood cancer treatment
I'm PortAI, I can summarize articles.
AbbVie has submitted a new biologics license application to the US FDA for its investigational drug Pivekimab sunirine (PVEK) aimed at treating blast plasmacytoid dendritic cell neoplasm (BPDCN). This application is based on data from the Phase 1/2 CADENZA trial, which assessed PVEK's safety and efficacy in treating this rare and aggressive blood cancer. The drug targets CD123, a protein overexpressed in BPDCN, and is also being developed for other hematologic malignancies.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments